Current Report Filing (8-k)
11 1월 2022 - 8:01PM
Edgar (US Regulatory)
0001372514
false
0001372514
2022-01-10
2022-01-10
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):
January 10, 2022
KIORA PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
|
001-36672
|
|
98-0443284
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
|
1371 East 2100 South
Suite 200
Salt Lake City, Utah 84105
|
|
84105
|
|
(Address of principal executive offices)
|
|
(Zip Code)
|
(781) 788-9043
(Registrant’s telephone number, including
area code)
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425
under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12
under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class:
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered:
|
|
Common Stock, $0.01 par value
|
|
KPRX
|
|
The Nasdaq Capital Market
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ¨
|
Item 7.01.
|
Regulation FD Disclosure.
|
Kiora Pharmaceuticals, Inc. (the “Company”) hereby furnishes
the updated investor presentation attached as Exhibit 99.1 to this Current Report on Form 8-K, which the Company may use in presentations
to investors from time to time.
The information furnished pursuant to Item 7.01, including Exhibit
99.1, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”) and will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the
Exchange Act, except to the extent that the Company specifically incorporates it by reference.
The information furnished in this report, including Exhibit 99.1, shall
not be deemed to constitute an admission that such information or exhibit is required to be furnished pursuant to Regulation FD or that
such information or exhibit contains material information that is not otherwise publicly available. In addition, the Company does not
assume any obligation to update such information or exhibit in the future.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
The Company hereby furnishes the following exhibit:
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
|
|
KIORA PHARMACEUTICALS, INC.
|
|
|
|
|
|
By:
|
/s/ Brian M. Strem, Ph.D.
|
|
|
|
Brian M. Strem, Ph.D.
|
|
|
|
President and Chief Executive Officer
|
|
|
|
|
|
Date: January 10, 2022
|
Kiora Pharmaceuticals (NASDAQ:KPRX)
과거 데이터 주식 차트
부터 12월(12) 2024 으로 1월(1) 2025
Kiora Pharmaceuticals (NASDAQ:KPRX)
과거 데이터 주식 차트
부터 1월(1) 2024 으로 1월(1) 2025
